Michelle Haas, MD

Associate Professor, Medicine-Infectious Disease


FacultyPhoto
Medical School
  • MD, University of Texas Medical School at Houston (2001)
Undergraduate School
  • BS, University of Texas–Austin (TX) (1996)
Internship
  • University of Colorado (2002)
Residency
  • University of Colorado, Chief Resident, Internal Medicine (2005)
Fellowships
  • University of California (San Diego) Program, Infectious Disease (2006)
  • University of Colorado, Infectious Disease (2009)
Languages
English
Department
Medicine-Infectious Disease

Publications

  • Aiona K, Bacon E, Podewils LJ, Haas MK. The disparate impact of age-based COVID-19 vaccine prioritization by race/ethnicity in Denver, Colorado. Health Policy Open. 2022 Dec;3:100074. PubMed PMID: 35892113
  • McDowell A, Haas M, Seaworth B, Wilson JW, Patrawalla A, Haley C, Lauzardo M, de Bruyn M, Goswami ND. Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013-2018. J Clin Tuberc Other Mycobact Dis. 2021 Feb;22:100201. PubMed PMID: 33336084
  • Haas MK, Ignatius EH, Stout JE, Dooley KE. Finding the right balance between efficacy and tolerability for TB treatment. Int J Tuberc Lung Dis. 2020 Nov 1;24(11):1225b-1226. PubMed PMID: 33172541
  • Gaensbauer J, Young J, Harasaki C, Aiona K, Belknap R, Haas MK. Interferon-Gamma Release Assay Testing in Children Younger Than 2 Years in a US-Based Health System. Pediatr Infect Dis J. 2020 Sep;39(9):803-807. PubMed PMID: 32804462
  • Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates with Self-administered Once-weekly Isoniazid-Rifapentine versus Daily Rifampin in Adults with Latent Tuberculosis. Clin Infect Dis. 2020 Sep 11. [Epub ahead of print] PubMed PMID: 32915203

Professional Memberships

  • Infectious Disease Society of America (IDSA), Member

Specialty Information

Specialties
  • Infectious Disease, Board Certification